A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.
In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.
While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.
As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”
Congratulations to the researchers and patients who made this important progress possible. 👏👏👏
Video Courtesy: @asco
First day PGY-1
Me: [orders 30 mEq potassium cause level is 3.7]
RN: we don't do 30, we do 20 or 40
Me: oh wow thanks, does it only come in 20s?
RN: no it comes in 10s
Me:
RN:
Me: cool, I'll change it to 20, thanks!
#TipsForNewDocs : choose laminar flow over turbulent
Today, with @BioNTech_Group, we announced positive topline results in adolescents 12-15 years of age from the Phase 3 Pfizer-BioNTech #COVID19 vaccine study.